ZOLL Reports Establishment of 10b5-1 Sales Plan by Chief Financial Officer

Zoll Medical Corporation (NasdaqGS: ZOLL), a manufacturer of resuscitation devices and related software solutions, today reported that A. Ernest Whiton, its Chief Financial Officer and Vice President of Administration, is entering into a 10b5-1 sales plan for the sale of shares of ZOLL common stock over an approximate 12-month period. Under the plan, it is anticipated that approximately 60,000 shares will be sold but it is possible that under certain market conditions, the number of shares sold under the Plan may increase to up to 90,000 shares. Sales under the plan are expected to commence in the third quarter of fiscal 2010. The shares to be sold will be acquired upon the exercise of a portion of stock options which were granted to Mr. Whiton over the past eight years. This new plan follows 10b5-1 sales plans entered into by Mr. Whiton in 2006, 2007 and 2008.

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are "forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled "Risk Factors” in the Company's Annual Report on Form 10-K filed with the SEC on December 10, 2009. You should not place undue reliance on the forward looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

©2010 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL is a registered trademark of ZOLL Medical Corporation.